<DOC>
	<DOCNO>NCT01801904</DOCNO>
	<brief_summary>The purpose study assess panitumumab active enough warrant comparative study patient metastatic colorectal cancer progress treatment cetuximab .</brief_summary>
	<brief_title>A Phase 2 Study Panitumumab Patients With Cetuximab-refractory Metastatic Colorectal Cancer</brief_title>
	<detailed_description>The study amend modification inclusion criterion ( wild-type tumor KRAS gene wild-type RAS gene , include KRAS NRAS exon 2 , 3 4 ) RAS mutational status tumor patient enrol amendment 1 approval centrally revise . Patients whose tumor result RAS mutate biomarkers central revision , replace . Therefore , overall sample size stage may higher one initially plan .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Pathologic diagnosis metastatic colorectal adenocarcinoma wildtype RAS tumor ( mutational status determine experienced laboratory use validated test method detection KRAS exons 2 , 3 , 4 , NRAS exons 2 , 3 , 4 Failure previous treatment fluoropyrimidine , oxaliplatin irinotecan . Patients may may treat bevacizumab . Documented disease progression follow treatment cetuximab patient show either objective response 8 week stable disease 16 week cetuximab treatment . Age least 18 year ECOG Performance Status 02 Neutrophils least 1,500 mm3 , platelet least 100,000 mm3 , hemoglobin least 9 g/dL Bilirubin level le 1.5 time ULN AST ( SGOT ) ALT ( SGPT ) great 2.5 time ULN ( 5 time ULN presence liver metastasis ) Serum creatinine less 1.5 time ULN Effective contraception , risk conception exist Life expectancy least 3 month Written inform consent Symptomatic brain metastasis Interstitial pneumonitis pulmonary fibrosis Any malignancy within 5 year ( except adequately treat carcinoma situ cervix non melanoma skin cancer ) Chemotherapy , radiotherapy immunotherapy within past 4 week Any unstable systemic disease ( include active infection , significant hepatic , renal metabolic disease ) , metabolic dysfunction , physical examination finding , clinical laboratory find contraindicates use study drug render patient high risk treatment complication Subject pregnant breast feeding , plan become pregnant within 6 month end treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>cetuximab-refractory</keyword>
</DOC>